

# **PS 2.4**



#### | BACKGROUND

Data is an essential resource, and just as important to health and development as any other, including energy, minerals, and raw materials. In the health sector, data is critical to analysis and advancement of all kinds. Data is increasingly important as more and more technologies and services, and innovations are built on it. Everything from generative AI to pharmaceutical trials to effective regulation is centered on data. Accordingly, the control of data is increasingly contested, whether because of commercial interests, public goods, or as the foundation of democratic societies. The growing contestation in all areas, including in population health and health care creates many challenges. include equity and ethical controversies such as data colonialism, ownership of data, and biases from inequities in data collection, management, use and application.

Digital coloniality refers to the unfair and unequal exercise of power over data and its benefits, where data can be seen as similar to any other extractive industry. As with gold and other precious ores, data is mined in developing countries and sent to rich countries, where it is refined into credit-bearing forms and used for career advancement, exploited economically, and controlled with legal and technical measures. In general, this means that the use of data benefits technology conglomerates and other organizations located in the global north, with few if any benefits accruing to the people whose bodies, lives, and experiences comprise the original resource. Moreover, with the development partners and international organizations being the most frequent users with high levels of demand and main financiers of information systems, concerns arise that this may crowd out domestic needs and utilization by and for these countries. The claim of local ownership rises as an issue, particularly in access to and application of data for health benefits. On the other hand, local capacity in data collection, management, and analyses remains a test to the local ownership issue.

Adding to this concern is the understanding of local context in cases of data science experts who are geographically or sociodemographically distant from the data subjects. Unintended (and sometimes intentional) bias against vulnerable populations and representation bias can arise from such situations. Additionally, the development of advanced data infrastructures such as machine learning and artificial intelligence may focus more on machine-readable data while overlooking the local forms and data on paper, which is still used in many low- and middle-income countries.

To address these expanding issues, strategies that consider domestic health needs and address representation and ownership problems are needed to improve the availability, accessibility, and usefulness of data local capacity in data collection and use to ensure the equitable and ethical application of quality data for health. Quality and balance of datasets, inclusion of gender dimensions and socio-cultural aspects, as well as dedicated public policies will need to be considered to tackle the biases, particularly against the vulnerable populations.

This session will confront the data colonialism, ownership, and hidden biases that come with the power of data and posit the reasons behind them. Upon better understanding the situations, speakers will also discuss actionable recommendations to minimize concerns in the data science world.

## | OBJECTIVES

- To understand the shifting challenges and concerns regarding equity and ethical issues related to data use in technology and AI for health
- To explore solutions and resources needed to ensure that equity, ethics, and gender considerations are effectively incorporated into the design, implementation and oversight of data for health
- To examine the enabling environment and local capacity needed to ensure the availability of data and information systems to promote equitable access to health for all especially in vulnerable populations and low-income countries





#### Moderator

### Peter H. Kilmarx

Acting Director for Fogarty International Center and Acting Associate Director for International Research

National Institutes of Health United States of America

Peter Kilmarx, an expert in global health and infectious disease research, policy, and programs, is the Deputy Director of the John E. Fogarty International Center at the U.S. National Institutes of Health, a preeminent center for global health research, partnership, and capacity strengthening. He previously served as the Country Director in Zimbabwe and earlier in Botswana for the U.S. Centers for Disease Control and Prevention (CDC) and as Chief of CDC's Sexual Transmission Research Section in Thailand. Other CDC leadership positions included Senior Advisor to the Director for Health Reform and Chief of Epidemiology Branch, both in the Division of HIV/AIDS Prevention. Dr. Kilmarx served in leadership roles in CDC's Ebola response efforts in the Democratic Republic of Congo (DRC), Sierra Leone, and Guinea. Dr. Kilmarx served for more than 20 years in the U.S. Public Health Service, rising to the rank of Rear Admiral (Assistant Surgeon General). After earning his M.D. from Dartmouth-Brown's Combined Program in Medicine, Dr. Kilmarx completed both his internal medicine residency and infectious disease clinical fellowship at Johns Hopkins Hospital.